Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation

Carlos Solorzanoa,b,1, Chenggang Zhu,b,1, Natalia Battistaa,c,d, Giuseppe Astarita,a Alessio Lodola,a Silvia Rivara,a Marco Mor,a Roberto Russob,2, Mauro Maccarronec,d, Francesca Antonietti, Andrea Duranti,a Andrea Tontinif, Salvatore Cuzzoc,a Giorgio Tarzia1, and Daniele Piomellia,b,h,3

Departments of aPharmacology and bBiological Chemistry, University of California, Irvine, CA 92697-4624; cDepartment of Biomedical Sciences, University of Teramo, I-64100 Teramo, Italy; dEuropean Centre for Brain Research Institute of Di Roviero e Cura a Carattere Scientifico (IRCSS) S. Lucia Foundation, I-00179 Rome, Italy; ePharmaceutical Department, University of Parma, I-43100 Parma, Italy; fInstitute of Medicinal Chemistry, University of Urbino “Carlo Bo”, I-61029 Urbino, Italy; gIRCSS Centro Neurolesi “Bonino-Pulejo,” I-98100 Messina, Italy; and hDrug Discovery and Development, Italian Institute of Technology, I-16163 Genova, Italy

Edited by L. L. Iversen, University of Oxford, Oxford, United Kingdom, and approved October 6, 2009 (received for review July 7, 2009)

Identifying points of control in inflammation is essential to discovering safe and effective antiinflammatory medicines. Palmitoylethanolamide (PEA) is a naturally occurring lipid amide that, when administered as a drug, inhibits inflammatory responses by engaging peroxisome proliferator-activated receptor-α (PPAR-α). PEA is preferentially hydrolyzed by the cysteine amidae N-acylethanolamine-hydrolyzing acid amidase (NAAA), which is highly expressed in macrophages. Here we report the discovery of a potent and selective NAAA inhibitor, N-[(3S)-2-oxo-3-oxetanyl]-3-phenylpropamid (S)-OOPP, and show that this inhibitor increases PEA levels in activated leukocytes and blunts responses induced by inflammatory stimuli both in vitro and in vivo. These effects are stereoselective, mimicked by exogenous PEA, and abolished by PPAR-α deletion. (S)-OOPP also attenuates inflammation and tissue damage and improves recovery of motor function in mice subjected to spinal cord trauma. The results suggest that PEA activation of PPAR-α in leukocytes serves as an early stop signal that contrasts the progress of inflammation. The PEA-hydrolyzing amidase NAAA may provide a previously undescribed target for antiinflammatory medicines.

NAAA | oleoylethanolamide | PPAR-α

Soon after its isolation from plant tissues (1), palmitoylethanolamide (PEA) was shown to reduce allergic reactions and inflammation in animals (2) and was briefly used to treat influenza symptoms in humans. Interest in the properties of this lipid amide lessened, however, until the characterization of its antiinflammatory (3), analgesic (4), and neuroprotective (5) effects and the identification of peroxisome proliferator-activated receptor-α (PPAR-α) as its primary molecular target (6, 7). Like other members of the nuclear receptor superfamily, PPAR-α is activated through ligand binding, which promotes heterodimer formation with the 9-cis-retinoic acid receptor, recruitment of coactivators into a multiprotein complex, and regulated expression of responsive genes. PPAR-α controls transcriptional programs involved in the development of inflammation through mechanisms that include direct interactions with the proinflammatory transcription factors NF-κB and AP1, and modulation of IκB function (8). Pharmacologic studies have demonstrated that PPAR-α agonists are therapeutically effective in rodent models of inflammatory and autoimmune diseases (9). Furthermore, mutant PPAR-α-deficient mice seem to be vulnerable to various inflammatory stimuli (9), suggesting that endogenous PPAR-α activity negatively regulates the initiation of acute inflammatory responses.

The multifunctional ligand-binding pocket of PPAR-α allows this protein to recognize 3 distinct classes of natural agonists: nonesterified fatty acids, which activate PPAR-α with potencies in the micromolar range (median effective concentration, EC50, 2–20 μM) (10); oxygenated fatty acids, such as (8S)-hydroxy-eicosatetraenoic acid (11) and (8R)-hydroxy-eicosatetraenoic acid (12) (EC50 0.3–1 μM); and lipid amides such as PEA and its analog oleoylthanolamide (OEA) (EC50 0.1–3 μM) (6, 13). Inmate immune cells produce significant amounts of PEA and OEA (14) and express a selective phospholipase D (PLD) that releases these endogenous PPAR-α agonists from their membrane phospholipid precursor, N-acylphosphatidylethanolamine (NAPE) (15). Inflammatory cells also express 2 intracellular amidases that have been implicated in lipid amide degradation: fatty-acid amide hydrolase (FAAH) (16) and N-acylthanolamine-hydrolyzing acid amidase (NAAA) (17, 18). Potent FAAH inhibitors, such as the compound URB597 (19), have been used to unmask the functions of the substrate preferred by FAAH, the endogenous cannabinoid agonist anandamide (20, 21). By contrast, effective inhibitors of intracellular NAAA activity, which preferentially recognizes PEA (17), have not been reported yet, and the roles played by endogenous PEA in the control of inflammatory responses remain unknown.

Results

Discovery of a Potent and Selective NAAA Inhibitor. NAAA is a cysteine hydrolase that belongs to the N-terminal nucleophile (Ntn) family of enzymes (17, 22). To discover new NAAA inhibitors, we generated a 3-dimensional model of the catalytic site of NAAA (Fig. L4) using the crystallographic coordinates of conjugated bile acid hydrolase (CBAH), another Ntn cysteine hydrolase that shares with NAAA a highly conserved sequence in the catalytic N-terminal region (Fig. S1) (23–26). According to our model, the tetrahedral intermediate formed through attack of catalytic cysteine 131 (17) on PEA is stabilized by electrostatic interactions between the carbonyl oxygen of PEA and the enzyme oxanion hole, which includes the side-chain...
amidic of the conserved asparagine 292 and the backbone amidic of asparagine 209. Aspartate 150 is involved in the stabilization of C131, whereas a hydrophobic pocket lined by tyrosine 151, among other residues, accommodates the flexible acyl chain of PEA. Site-directed mutagenesis experiments confirmed that C131, N292, and D150 are essential for NAAA function because the mutants C131A, C131S, N292A, and D150E were devoid of enzyme activity (Fig. 1B). Moreover, the negative impact of mutations targeting Y151 (Y151A and Y151F) supports a contribution of the presumptive acyl chain-binding pocket to enzyme function (Fig. 1B). Control mutations distal to the active site, such as alanine 176 (A176G), had no effect on NAAA activity (Fig. 1B). We used the active-site properties predicted by our model to select a set of commercial molecules, which were then tested for their ability to inhibit NAAA. Although the enzyme was insensitive to most agents—including the FAAH inhibitor URB597 (Fig. 2A)—the screening in cellular PEA (Fig. 2C) revealed that the ability of asparagine 209 and asparagine 292 to inhibit NAAA also depended on the β-lactone group of compound 1 as an NAAA inhibitor of low micromolar potency (Fig. 2A and Table 1).

The β-lactone group of compound 1 binds covalently the catalytic cysteine of hepatitis A virus proteinase 3C, blocking its activity (28). Focused structure–activity relationship studies revealed that the ability of 1 to inhibit NAAA also depended on the β-lactone ring, rather than the carbamate fragment, because opening the β-lactone abrogated inhibitory activity (Table 1, compound 2), whereas removing the carbamate group yielded a compound [N-(3S)-2-oxo-3-oxetanyl]-3-phenylpropanamide; (S)-OOPP] that was significantly more potent than 1 at inhibiting NAAA (Fig. 2A and Table 1, compound 3). The role of the β-lactone was confirmed by the inactivity of the cyclobutanone and cyclobutane analogs of (S)-OOPP, compounds 4 and 5 (Table 1). Moreover, the markedly diminished potency displayed by the enantiomer, (R)-OOPP (Fig. 2A and Table 1, compound 6), highlighted the selective recognition of (S)-OOPP by NAAA. Such selectivity might account for the weak interaction of the inhibitor with acid ceramidase (IC50 = 10.9 ± 3.1 μM; n = 4), a cysteine amidase that is both structurally and functionally related to NAAA (17). In addition, (S)-OOPP did not inhibit FAAH (IC50 >100 μM) or several other serine hydrolases that use lipids as substrates (Table S2). Kinetic analyses revealed that (S)-OOPP blocks NAAA through a noncompetitive mechanism (Fig. 2B). The results indicate that (S)-OOPP is a potent, selective, and noncompetitive NAAA inhibitor.

**NAAA Inhibition Normalizes PEA Levels in Activated Inflammatory Cells.** To test whether (S)-OOPP inhibits NAAA activity in intact cells we first induced a localized inflammatory response in mice by implanting s.c. polyethylene sponges instilled with the proinflammatory polysaccharide carrageenan. Three days after surgery, we collected infiltrating cells—mostly neutrophils (90.3% ± 2.0%) and macrophages (6.1% ± 0.9%, mean ± SEM; n = 4)—and analyzed their lipid content by liquid chromatography/mass spectrometry (LC/MS). Consistent with previous results (29, 30), the chemoattractant caused a marked decrease in cellular PEA (Fig. 2C). The limited plasma stability of (S)-OOPP (half-life <1 min) precluded its systemic administra-

**Table 1. Structures of selected NAAA inhibitors**

<table>
<thead>
<tr>
<th>Comp</th>
<th>R</th>
<th>R1</th>
<th>IC50 (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
<td>2,960 ± 300</td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td>&gt;100,000</td>
</tr>
<tr>
<td>3 (S)-OOPP</td>
<td></td>
<td></td>
<td>420 ± 20</td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td>&gt;100,000</td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
<td>&gt;100,000</td>
</tr>
<tr>
<td>6 (R)-OOPP</td>
<td></td>
<td></td>
<td>6000 ± 600</td>
</tr>
</tbody>
</table>

Values reported are the concentrations required to inhibit NAAA activity by 50% (IC50) in nM and are expressed as mean ± SEM of at least three independent experiments. They were calculated from concentration response curves using nonlinear regression analysis in the Prism 4.0 software package.
tion in vivo, but when the compound was instilled into the sponge (25 µg per sponge) it prevented in a stereoselective manner the carrageenan-induced reduction in leukocyte PEA levels (Fig. 2C), suggesting that it effectively inhibited NAAA activity in these cells. In additional experiments, we stimulated RAW264.7 macrophages in cultures with LPS, which also caused a reduction in cellular PEA content (Fig. 2D). Incubation with (S)-OOPP, but not (R)-OOPP (each at 10 µM), inhibited NAAA activity in these cells, as assessed ex vivo using a standard enzyme assay (Fig. S2A), and blocked the LPS-reduced PEA levels in RAW264.7 cells (Fig. 2D). Furthermore, wild-type mice displayed normal suppression of leukocyte infiltration and PEA levels in NAAA-overexpressing HEK293 cells exposed to the calcium ionophore ionomycin (Fig. S2B). That the effects of (S)-OOPP on PEA levels were restricted to cells stimulated with LPS or ionomycin suggests that inflammatory triggers might activate NAAA (through autoproteolysis or other posttranslational modifications) or facilitate its access to cellular pools of PEA. Finally, treatment with (S)-OOPP did not affect the levels of the endocannabinoid anandamide, which were increased by LPS (Fig. S2C) (15), or those of ceramide (Fig. S3), confirming that (S)-OOPP preferentially inhibits NAAA over other lipid amides, such as FAAH and acid ceramidase.

NAAA Inhibition Reduces Neutrophil Migration. The discovery of (S)-OOPP allowed us to ask whether preventing PEA hydrolysis by NAAA might modulate inflammatory responses. Addition of (S)-OOPP to carrageenan-containing sponges increased PEA levels and inhibited leukocyte migration in a dose-dependent and stereoselective manner (Fig. 3A and B). Histologic analyses showed that (S)-OOPP selectively reduced the infiltration of neutrophils into the sponges (Fig. S4). (S)-OOPP also inhibited plasma extravasation induced by carrageenan (Fig. S5A). The ability of (S)-OOPP to decrease inflammatory responses was likely mediated by endogenous PEA acting as an agonist at PPAR-α. Consistent with this idea, we found that the antiinflammatory effects of (S)-OOPP were abrogated by targeted PPAR-α deletion (Fig. 3C), which did not influence PEA production (Fig. 3D), and were mimicked either by exogenous PEA or the synthetic PPAR-α agonist GW7647 in a PPAR-α-dependent manner (Fig. 4). Notably, (S)-OOPP did not directly stimulate PPAR-α in a cellular transactivation assay (EC50 > 100 µM) and did not inhibit the eicosanoid-synthesizing enzymes cyclooxygenase-2 and 5-lipoxygenase (IC50 > 100 µM). We have not yet identified the precise cellular site of action of (S)-OOPP. In RAW264.7 cells show, however, that the compound reduces LPS-induced expression of iNOS, but not TNF-α (Fig. S5 B and C), which suggests that NAAA inhibition in activated macrophages may normalize PEA levels and blunt signaling downstream of TNF-α, as previously suggested for direct-acting PPAR-α agonists (31).

Effects of FAAH Inhibition. PEA is a preferred substrate for NAAA but can also be hydrolyzed by FAAH (16). To assess the contribution of FAAH to PEA hydrolysis in inflammatory cells, we tested the effects of the FAAH inhibitor URB597 (20). Even though leukocytes express FAAH (32), administration of URB597 neither affected PEA levels nor counteracted the proinflammatory effects of carrageenan in vivo (Fig. S6 A–C) or those of LPS in vitro (Fig. S6 D and E). Previous studies have shown that mutant mice lacking peripheral FAAH have a reduced sensitivity to various inflammatory challenges (33). We found, however, that FAAH−/− mice display normal suppression of PEA levels (Fig. S6F) and normal neutrophil infiltration and plasma extravasation in response to carrageenan (Fig. S6 G and H). We interpret these results to indicate that, under our experimental conditions, FAAH does not play an obligatory role in the degradation of PEA by activated leukocytes.

NAAA Inhibition Reduces Spinal Cord Injury. To further characterize the antiinflammatory properties of (S)-OOPP, we determined the effects of this compound on the tissue response produced by traumatic spinal cord injury (SCI) in mice, which is known to be accompanied by profound inflammation (34) and changes in PEA levels (35). We induced SCI by applying vascular clips to the dura mater via a 4-level T1–T4 laminectomy (36). This resulted in marked neutrophil infiltration, production of inflammatory mediators, apoptosis, and edema (Fig. 5 A–G and Fig. S7). Previous studies have shown that these effects are reduced by administration of exogenous PEA and are magnified in PPAR-α−/− mice (36). Two consecutive intrathecal injections of (S)-OOPP (30 µg per mouse, 1 and 6 h after SCI induction) strongly reduced tissue injury (Fig. 5 A–D) and inhibited expression of inflammation and apoptosis markers, such as iNOS, tissue
Is PEA signaling at PPAR-α relevant to human inflammatory states? An initial answer to this question, which will require further experimental confirmation, is provided by a recent report showing that the levels of PEA found in synovial fluid from rheumatoid arthritis and osteoarthritis patients are strikingly lower than those measured in healthy subjects (43). Because experimental inflammatory triggers also decrease PEA levels in animals, it is tempting to speculate that a deficit in PEA signaling may contribute to the pathogenesis of chronic inflammation. If this is the case, then pharmacologic strategies aimed at correcting a deficit in PEA/PPAR-α signaling might provide a new mechanism for the treatment of inflammatory disorders. One such strategy consists in activating PPAR-α by the use of potent and selective receptor agonists (9). However, the prolonged clinical use of these agents has been linked to a variety of untoward effects, which include oncogenesis, renal dysfunction, rhabdomyolysis, and cardiovascular toxicity (44). A possible alternative might be to magnify endogenous PEA activity at PPAR-α by protecting this lipid amide from NAAA-catalyzed degradation. The present findings, demonstrating that NAAA blockade reduces inflammatory responses in various experimental models, provisionally validate the latter approach. Notably, our results show that genetic or pharmacologic interruption of FAAH activity does not prevent the proinflammatory effects of LPS in vitro or those of carrageenan in vivo, implying that FAAH may not contribute to the termination of PEA signaling in those models. However, genetically modified mice that lack FAAH in peripheral tissues display a hypoinflammatory phenotype (33), and antiinflammatory effects of FAAH inhibitors have been reported in other models (45), which suggests that the roles played by FAAH and NAAA in regulating inflammation might be context dependent.

In conclusion, inhibition of NAAA activity by (S)-OOPP reveals a role for endogenous PEA as a negative regulator of tissue responses to proinflammatory stimuli. The decrease in synovial PEA levels observed in rheumatoid arthritis and osteoarthritis patients (43) suggests that this mechanism may be disrupted in human inflammatory pathologies. A second generation of systemically active NAAA inhibitors—possibly derived from the scaffold provided by (S)-OOPP—might help combat inflammation by correcting deficits in PEA signaling.

Materials and Methods

**Compound Syntheses.** (S)-OOPP and (R)-OOPP were prepared in 3 steps from N-Boc-L-serine and N-Boc-D-serine, respectively. Mitsunobu (46) cyclization of these products gave lactone intermediates, which were deprotected and salified (47). Coupling of the resulting tosylates with 3-phenylpropionyl chloride according to standard procedures (48) afforded the desired compounds. Compound 5 was synthesized similarly from 3-phenylpropionyl chloride and cyclobutylamine. A published procedure (49) for the synthesis of benzoylcarbonylanocyclobutanone was applied to the synthesis of compound 4, which was obtained from the reaction of bis(trimethylsilyloxy)cyclobutene and 3-phenylpropionamide. Additional synthetic details will be provided elsewhere. A first batch of N-(cyclohexylcarbonyl)pentadecylamine was purchased from Cayman Chemicals, and a second one was prepared according to a published procedure (17) and purified by flash chromatography (silica gel; cyclohexane/ethyl acetate 8:2). The compound yielded white crystal needles, an Mp of 89 °C (in acetone) and a single peak (m/z 338) by LCMS, positive electrospray ionization (MS+). The 1H NMR (CDCl3) spectrum revealed minor differences relative to the published 1H NMR (CDCl3) (d) δ = 0.88 ppm, 3H, J = 6.5 Hz), 1.21–1.51 ppm (m, 31H), 1.69–1.89 ppm (m, 5H), 1.98–2.11 ppm (m, 1H), 3.18–3.28 ppm (m, 2H), 5.44 (br s, 1H) ppm. Neither batch significantly inhibited recombinant NAAA activity in our tests. Solvents were from Burdick and Jackson.

**Molecular Modeling.** The amino acid sequence of the mature form of rat NAAA (nNAAA, amino acids 131–362 of Q5TKC7 in the SWISS-PROT/TrEMBL database) was used as a query for the automatic fold recognition server PHDRE (formerly known as 3D-PSSM). CBAH from Clostridium perfringens (28F in the Protein Data Bank) and resulted in the best reference template (identity score 11%, similarity score 23%). Limited modification of the 2D sequence align-

---

Solorzano et al. PNAS | December 8, 2009 | vol. 106 | no. 49 | 20969

---

**Discussion**

Previous studies have shown that PEA and other lipid amides activate the antiinflammatory nuclear receptor PPAR-α in a range of concentrations (0.1–3 µM) (6, 13) that occur normally in tissues (6, 14). Furthermore, exogenous PEA exerts profound antiinflammatory effects (3) that are mediated by PPAR-α (6), and mice lacking this receptor display a heightened sensitivity to inflammatory challenges and spinal cord trauma (37). The present report discloses a potent and selective inhibitor of the PEA-degrading enzyme, NAAA, and demonstrates that NAAA blockade normalizes PEA levels in activated inflammatory cells and dampens tissue reactions to various proinflammatory triggers. These results suggest that endogenous PEA acting at PPAR-α provides a no-go signal that hinders the development of acute inflammation. Such a role may be analogous to those documented for annexin-1 (38) and other antiinflammatory proteins (34, 39) but clearly differentiates PEA from known lipid mediators, which either incite the inflammatory process (e.g., prostaglandins) (31) or terminate it by promoting resolution and tissue healing (e.g., lipoxins and resolvins) (40, 41). Interestingly, a recent report suggests that circulating oleic acid may exert a tonic inhibitory tone on chemotaxis, although its mechanism of action has not been elucidated (42).
ment proposed by PHYRE allowed the superposition of 2 NAAAs asparagines (N209 and N292 in the rat) to N82 and N175 of CBAH, which play a critical role in the catalytic activity of CBAH. The resulting alignment was used to build 3-dimensional models of NAAAs using MODELLER 7.0 (50) and applying standard settings for loop modeling. The overall geometric quality of the structures was assessed by PROCHECK (51), and the NAAAs model having the highest G-factor was selected and used for modeling purposes. Hydrogen atoms were added by the Biopolymer module of Sybyl 7.2 (Tripos), choosing a pose consistent with bond formation between the carbonyl carbon of the substrate and the sulfur atom of C131, and accommodating the acyl chain within the lipophilic pocket corresponding to that occupied by the bile acid in the template. Position and conformation of PEA were then optimized by the Sybyl 7.2 Dock.minimize procedure and by energy minimization of the complex to an energy gradient of 0.2 kcal/(mol·Å). Starting from the Michaelis complex, the PEA-NAAAs tetraedral intermediate was built by imposing a covalent bond between the amide carbon atom and the sulfur atom of C131 and reassigning the atom types. The resulting structure was minimized to an energy gradient of 0.2 kcal/(mol·Å) and submitted to molecular dynamics simulation, using the force field MMFF94 implemented in Sybyl 7.2. A time step of 1 fs was applied with a nonbonded cutoff of 8 Å and dielectric constant set to 1. During the simulation, only the protein side chains and the ligand were allowed to move. A heating phase of 50 ps at 300 K was followed by 500 ps of simulation at the same temperature. The last snapshot structure was finally minimized using MMFF94 to an energy gradient of 0.2 kcal/(mol·Å) without restraints.

**Animals and Cells.** Male Swiss mice (20–25 g) were from Charles River, C57BL/6J wild-type mice and C57BL/6J PPAR-α(-/-) mice (B6.129S2-Ppara1Gont12) (20–25 g) were from Jackson Laboratories. All procedures met the National Institutes of Health guidelines for the care and use of laboratory animals and were approved by the University of California-Irvine Institutional Animal Care and Use Committee. HEK293 and RAW264.7 cells were from American Type Culture Collection and were cultured in DMEM (Invitrogen) supplemented with FBS (10%; Invitrogen).

**Animal Treatments.** *Carrageenan-induced inflammation*. Sterile polyethylene sponges (1 cm3) were implanted under the dorsal skin of mice. Carrageenan (0.1–1.0% in 90 μL sterile water per sponge), drugs, or vehicles (DMSO, 10 μL per sponge) were instilled into the sponges, wounds were sutured, and mice were allowed to recover. After 6–72 h, mice were killed and sponges collected. Exudate volume was measured, and cells were counted using a hemocytometer.

**Spinal cord injury.** Mice were anesthetized using chloral hydrate (400 mg/kg). Using the clip compression model described by Rivlin and Tator, we produced SCI by extradural compression of a section of the spinal cord exposed via a 4-level T5–T8 laminectomy, in which the prominent spinous process of T5 was used as a surgical guide. A 6-0 laminectomy was chosen to expedite timely harvest and to obtain enough tissue for biochemical examination. With the aneurysm clip applicator oriented in the bilateral direction, an aneurysm clip with a closing force of 24 g was applied extradurally at T5–T8 level. The clip was rapidly released with a clip applicator, which caused cord compression. In the injured groups, the cord was compressed for 1 min. After surgery, saline (1.0 mL) was administered s.c. After surgery, the mice were placed on a warm heating pad and were then singly housed in a temperature-controlled room at 27 °C for 10 days with food and water available ad libitum. During this time, the animals' bladders were manually voided twice per day until the mice were able to regain normal bladder function. Sham-injured animals were only subjected to laminectomy. Mice were randomized into groups of 10 each. Vehicle (saline) or (5-OOPP (30 μg per mouse) was administered intrathecally 1 h and 6 h after surgery. Animals were killed 24 h after surgery.

**Statistics.** Results are expressed as mean ± SEM of n observations. They were analyzed by one-way ANOVA followed by Bonferroni post hoc test for multiple comparisons. P values <0.05 were considered to be significant.

**Other Methods.** See SI Materials and Methods for remaining methods, including plasmid preparation, RNA extraction and real-time PCR, expression of recombinant proteins, protein analyses, enzyme assays, PPAR-α transactivation assay, lipid analyses, immunohistochemistry, TUNEL assay, light microscopy, and grading of motor disturbances.

**ACKNOWLEDGMENTS.** We thank Drs. J. Fu and K. M. Jung for experimental advice; and N. Barsegyan, A. Der Mugrdechian, and C. Van for assistance. Financial support was provided by grants from the Sandler Program for Asthma Research, and the National Institute on Drug Abuse (to D.P.); and from the University of Urbino and the Italian Ministry of Instruction, University and Research Grant 2005032713–002 (to G.T.).


